Home / Learn / Immunotherapy / View All IO Resources

View All IO Resources

Here is a comprehensive list of all of our immuno-oncology resources. Enter your search terms in the box below to filter your results.

Displaying results 61 - 80 of 120

Prev 1 2 3 4 5 6 Next
The advent of the immuno-oncology (I-O) programmed cell death protein (PD-1) and programmed death ligand-1 (PD-L1) checkpoint inhibitor therapies have transformed the treatment landscape of bladder cancer.
As the indications for and use of immuno-oncology (I-O) agents continues to expand, clinicians need to consider how best to create a supportive treatment environment in community cancer settings. The Institute of Clinical Immuno-Oncology (ICLIO) spoke with Joanne Riemer, RN, BSN, research nurse at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital.
June 1, 2017
Presenter: Christine M. Walko, PharmD, BCOP, FCCP, Personalized Medicine Specialist, and Chair, Clinical Genomic Action Committee, Moffitt Cancer Center. The discussion includes a review of systemic melanoma treatments and the use of immunotherapy checkpoint inhibitors in treating patients with melanoma and pre-existing autoimmune disorders. Also included is a case study discussion. View On-Deman…
ICLIO talks with Spencer D. Green, MS, MBA (HA), CMPE, Director, Oncology and Infusion Centers, and April Brager PharmD, BCOP, Oncology Pharmacy Coordinator, about how they created an environment to support their Immuno-Oncology program at Bozeman Health Deaconess Cancer Center.
This article provides an overview of strategies for building capacity to support information dissemination, timely reimbursement, and care coordination within the multidisciplinary care team.
This article provides an overview of the FDA-approved and emerging systemic treatment approaches for patients with HNSCC, to help oncologists and supportive healthcare providers stay abreast of the ever-changing treatment landscape.
May 18, 2017
View the archived webinar presentation given by Steven L. D’Amato, BScPharm, BCOP, Executive Director of the New England Cancer Specialists for an ICLIO webinar presentation on Immuno-Oncology Management Best Practices. Learn about evolving best practices in the delivery of immunotherapy for cancer. This webinar explores: clinical concerns (appropriate use of I-O agents, patient adherence a…
Drew Pardoll, MD, PhD talks to ICLIO about developments in the exciting field of immune checkpoints in cancer immunotherapy.
ICLIO talks with Dan Sherman, MA, LPC, a financial advocate at Mercy Lacks Cancer Center, about new reimbursement challenges with cancer immunotherapies.
This article briefly addresses the concept of palliative/supportive care, its role in comprehensive cancer care, and the interface of immuno-oncology (I-O) checkpoint therapy with palliative care needs.
Learn about the past, present, and future systemic treatment approaches for patients with predominately clear cell RCC in order to help oncologists and supportive healthcare providers stay abreast of this rapidly evolving field.
Joanne Buzalgo, PhD, Senior Vice President of Research and Training at Cancer Support Community (CSC) and a two-time cancer survivor, recently spoke to us about patient perspectives on living with advanced cancer and duration of therapy for patients with metastatic renal cell carcinoma (RCC).
April 20, 2017
View the archived webinar presentation given by Jared Weiss, MD,  School of Medicine, Assistant Professor, UNC-Chapel Hill, Clinical Research, Thoracic Oncology Program. Hear the current treatment algorithm for head and neck cancer and then hear the latest evidence for treating this patient population with immunotherapy checkpoint inhibitors. Learn about immuno-oncology agents in development,…
Value is a multidimensional term in healthcare that encompasses many meanings for different stakeholders. Robin B. Atkins, RN, OCN, an outpatient community oncology nurse , recently talked with the Institute for Clinical Immuno-Oncology (ICLIO) about what value means for nurses and patient care.
In the era of immunotherapeutics, the treatment of cancer is rapidly changing. Since 2011, the U.S. Food and Drug Administration has approved several immuno-oncology agents for treating patients with advanced cancer.
The search is ongoing for checkpoint inhibitor biomarkers that may play an increasing role in guiding patient selection for both monotherapy and combination immunotherapy, and in identifying early indicators of treatment response.
March 15, 2017
View the archived webinar presentation given by Marianne Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP, Assistant Professor of Nursing, Yale University School of Nursing. Learn about immune-related adverse events (irAEs) associated with immunotherapies used to treat patients with metastatic non-small cell lung cancer (NSCLC) and how to manage the irAEs most common to …
February 28, 2017
View the archived webinar presentation given by Sanjiv S. Agarwala, MD, Chief of Medical Oncology & Hematology at St. Luke’s Cancer Center and Professor of Medicine at Temple University School of Medicine This presentation builds on the ICLIO webinar, Therapeutic Approaches to Metastatic Melanoma.  Hear a review of current guidelines for adjuvant therapy for melanoma and practical co…
Read “Immuno-Oncology: There’s More to Discover,” and find out how ICLIO is already helping your colleagues to integrate delivery of immunotherapies into practice.
We spoke with Stacey Dobbs RN, BSN, the Oncology Clinical Trials Nurse Coordinator at W.G. "Bill" Hefner Veterans Administration Medical Center, about her her work as an infusion nurse and some of the challenges that patients receiving immunotherapy have faced.

Displaying results 61 - 80 of 120

Prev 1 2 3 4 5 6 Next